Pfizer

The price is not always right

Victoria Goldman provides an update on the latest news from the generics market

The price is not always right

Victoria Goldman provides an update on the latest news from the generics market

Paying through the nose

Last month we heard the unedifying news that pharmaceutical companies were ripping off the NHS by charging inflated prices for generic medicines. The practice was first revealed in June 2016 by The Times, but it took a further six months for the Competition and Markets Authority (CMA) to announce its decision to fine Pfizer a record £84.2m and Flynn Pharma an additional £5.2m for charging “excessive and unfair prices” for phenytoin capsules.

It seems incredible that generic medicines can be priced at levels many times higher than the cost of the original branded product.

Pfizer and Flynn fined £90m for phenytoin price hike

CMA imposes record fine on Pfizer and Flynn for charging excessive prices for phenytoin sodium capsules

Pfizer launches 'Kick it with help'

Pfizer enlists football professionals to promote expert stop smoking advice